Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2025-522707-26 | Registry Identifier | EU CTIS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.
This is a first-in-human, open-label, phase I/Ib, multi-center study consisting of a dose escalation part of IEV407 as a single agent (SA) and in combination with endocrine therapy (fulvestrant or letrozole) followed by a dose expansion part in patients with advanced breast cancer (aBC). The study will start with the evaluation of IEV407 as a SA.
Following evaluation of IEV407 in combination with fulvestrant through dose escalation and establishment of a recommended dose and/or dose ranges for optimization (RD/DRO), the study may proceed to the Phase Ib expansion part to evaluate the combination treatment of IEV407 with fulvestrant. If more than one treatment arm is open concurrently in the dose expansion part, a randomization schedule will be employed for patient allocation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dose escalation: IEV407 single agent | Experimental | IEV407 single agent |
|
| Dose escalation: IEV407 + fulvestrant | Experimental | IEV407 in combination with fulvestrant |
|
| Dose escalation: IEV407 + letrozole | Experimental | IEV407 in combination with letrozole |
|
| Dose expansion, recommended dose (RD)-1: IEV407 + fulvestrant | Experimental | IEV407 in combination with fulvestrant |
|
| Dose expansion, RD-2 (optional dose optimization): IEV407 + fulvestrant | Experimental | IEV407 in combination with fulvestrant |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| IEV407 | Drug | Oral administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and severity of dose-limiting toxicities (DLTs) | Number of participants with DLTs. A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher, including death, unless clearly and incontrovertibly assessed as due to disease, disease progression, inter-current illness/injury, concomitant medications, or extraneous causes, that occurs within the first 28 days of treatment with IEV407 in the dose escalation parts or in the expansion part of IEV407 in combination with fulvestrant with the exceptions described in the study protocol. | 28 days |
| Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Number of participants with AEs and SAEs, including changes in laboratory values, vital signs and echocardiograms (ECGs) qualifying and reported as AEs. | Up to approximately 2 years |
| Frequency of dose interruptions, reductions and discontinuations | Number of participants with dose adjustments (interruptions, reductions, or permanent discontinuation) as a measure of tolerability. | Up to approximately 2 years |
| Dose intensity | Dose intensity defined as the ratio of actual cumulative dose received and actual duration of exposure. | Up to approximately 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Best Overall Response (BOR) | BOR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) is defined as the best overall confirmed response recorded from the start of the treatment until progressive disease (PD), death, start of new therapy, withdrawal of consent or end of study, whatever comes first. Efficacy will be based on the investigator assessment. | Up to approximately 2 years |
Not provided
Inclusion Criteria:
Age ≥ 18 years old
Patients with one of the following indications:
HR+/HER2- aBC with disease progression on or following, or have been intolerant to, at least one line of endocrine-based therapy in combination with a CDK4/6 inhibitor and at least one additional line of systemic therapy in the unresectable/metastatic setting and not be a candidate for any available standard therapy, in the investigator's judgement.
- Dose expansion of IEV407 in combination with fulvestrant: HR+/HER2- aBC with disease progression on or following, or have been intolerant to, endocrine-based therapy in combination with a CDK4/6 inhibitor. They must not have received more than two prior lines of endocrine-based therapy in the unresectable/metastatic setting. Prior cytotoxic chemotherapy and/or antibody-drug conjugate therapies in the unresectable/metastatic setting are not allowed.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Novartis Pharmaceuticals | Contact | 1-888-669-6682 | novartis.email@novartis.com | |
| Novartis Pharmaceuticals | Contact | +41613241111 |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mary Crowley Cancer Research | Recruiting | Dallas | Texas | 75251 | United States |
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000077267 | Fulvestrant |
| D000077289 | Letrozole |
| ID | Term |
|---|---|
| D004958 | Estradiol |
| D004963 | Estrenes |
| D004962 | Estranes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fulvestrant | Drug | Intramuscular injection. Approved medication. |
|
|
| Letrozole | Drug | Oral administration. Approved medication. |
|
|
| Overall Response Rate (ORR) | ORR per RECIST v1.1 is defined as the proportion of patients with a BOR of Complete response (CR) or Partial response (PR). Efficacy will be based on the investigator assessment. | Up to approximately 2 years |
| Disease Control Rate (DCR) | DCR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or Stable Disease (SD). Efficacy will be based on the investigator assessment. | Up to approximately 2 years |
| Clinical Benefit Rate (CBR) | CBR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or an overall lesion response of SD or Non-CR/Non-PD which lasts for at least 24 weeks. Efficacy will be based on the investigator assessment. | Up to approximately 2 years |
| Duration of Response (DOR) | DOR per RECIST v1.1 is the time between the first documented response (CR or PR) and the date of progression by local review as applicable or death due to any cause. Efficacy will be based on the investigator assessment. | Up to approximately 2 years |
| Progression Free Survival (PFS) | PFS per RECIST 1.1 is defined as the time from the date of start of study treatment (Phase I) or the date of randomization (Phase II) to the date of the first documented progression or death due to any cause. Efficacy will be based on the investigator assessment. | Up to approximately 2 years |
| Maximum plasma concentration (Cmax) of IEV407 | Pharmacokinetic (PK) parameters based on plasma concentrations of IEV407. | From pre-dose up to 24 hours after dosing on Cycle 1 Day 1 and Day 15. 1 cycle = 28 days |
| Area under the plasma concentration-time curve (AUC) of IEV407 | PK parameters based on plasma concentrations of IEV407. | From pre-dose up to 24 hours after dosing on Cycle 1 Day 1 and Day 15. 1 cycle = 28 days |
| Novartis Investigative Site | Recruiting | Hirakata | Osaka | 5731191 | Japan |
| Novartis Investigative Site | Recruiting | Singapore | 119074 | Singapore |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D045166 | Estradiol Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009570 | Nitriles |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |